Eagle Genomics Enters Administration, Up for Sale Amid Fiscal Challenges

Strategic Insights -

Eagle Genomics, a leading data science genomics company, has fallen into administration, marking the beginning of a sale process after struggling to adapt its business model. Founded in 2008 by Abel Ureta-Vital and Will Spooner, the company developed e[datascientist], a platform leveraging network science, AI, and hypergraph technologies to drive life science innovation and R&D. With close relationships established with academics, hospitals, and the European Bioinformatics Institute, Eagle Genomics had secured significant funding, including a $20m raise in 2022 and an additional £3m in 2023. However, the company's ambitious transition to a software as a service (SAAS) model and its diversification into the microbiome area led to financial difficulties, ultimately resulting in its administration.

Key Takeaways:

  • Eagle Genomics, a data science genomics company founded in 2008, has entered administration, marking the beginning of a sale process.
  • The company developed e[datascientist], a platform leveraging network science, AI, and hypergraph technologies to drive life science innovation and R&D.
  • Close relationships were established with academics, hospitals, and the European Bioinformatics Institute.
  • The company secured significant funding, including a $20m raise in 2022 and an additional £3m in 2023.
  • Eagle Genomics' transition to a software as a service (SAAS) model and diversification into the microbiome area led to financial difficulties.
  • Former CEO Anthony Finbow is now "chief evangelist," while Dr. Victoria Kimonides took over as CEO in September 2023.
  • JW Colley and JA Dickinson, of CBW Recovery LLP, were appointed joint administrators of the company on March 20, 2024.
  • A purchaser is being worked with to acquire the company's business and assets.
  • Founder Abel Ureta-Vital and board member Will Spooner established the company as a tribute to the Eagle pub where the double helix structure of DNA was announced in 1953.
  • The company's CEO, Anthony Finbow, championed the potential of the microbiome in addressing various challenges in food and beverages, agriculture, health, and nutrition.

Statistics:

  • Eagle Genomics' fixed assets were valued at £111,337 in March 2024.
  • Current assets totaled £3.4 million at that time.
  • Total assets less current liabilities amounted to £1.96m.
  • The company raised $20m in 2022.
  • An additional £3m fundraise occurred in September 2023.
  • Eagle Genomics developed close relationships with 200+ academics, 150+ hospitals, and the European Bioinformatics Institute.

Sources:

  • Eagle Genomics press release, "Eagle Genomics Enters Administration"
  • Cambridge Independent, "Eagle Genomics falls into administration"
  • "Anthony Finbow is now entrepreneur in residence with Founders at the University of Cambridge"